Alnylam Pharmaceuticals Stock Rises as FDA Lifts Study Hold
Alnylam Pharmaceuticals Inc.'s (ALNY) stock rose 5.9% premarket Friday after the company said the U.S. Food and Drug Administration lifted its clinical hold on studies with Alnylam's hemophilia treatment, fitusiran. Alnylam and the FDA had previously reached an agreement to mitigate risk during studies. Alnylam is working with Sanofi Genzyme, the specialty care unit of Sanofi SA (SAN.FR), on the treatment. Sanofi shares are down 1% Friday. (firstname.lastname@example.org; @CaraRLombardo)
(END) Dow Jones Newswires
December 15, 2017 07:46 ET (12:46 GMT)Copyright (c) 2017 Dow Jones & Company, Inc.